{
    "clinical_study": {
        "@rank": "62105", 
        "acronym": "MTH01", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "description": "> or = 90 days  to < 2 years on enteral methadone. Dose schedule is per routine medical care."
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "2 years to < 6 years on enteral methadone. Dose schedule is per routine medical care. Will include overweight children with BMI for age of 85 - 95 percentile, or obese children BMI for age > or = to 95 percentile."
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "6 years to < 18 years on enteral methadone. Dose schedule is per routine medical care. Will include overweight children with BMI for age of 85 - 95 percentile, or obese children BMI for age > or = to 95 percentile."
            }
        ], 
        "biospec_descr": {
            "textblock": "The Study team is interested in learning more about how genetic differences in proteins\n      known as cytochrome P450 enzymes effect the breakdown of methadone. The study team will\n      gather leftover blood collected from the infant or child while the infant/child was in this\n      study and send it to a laboratory to test for genetics. There will be no extra blood draws\n      for this part of the study.\n\n      The samples for genetic testing will be given a code number and will not be labeled with the\n      infant or child's name or initials, or any other information that could identify the infant\n      or child. Any remaining blood will be destroyed after the genetic laboratory testing is\n      complete."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to learn more about how the study drug, methadone, prescribed\n      by an infant's or child's physician as part of standard medical care, is processed in\n      children and young adults.  While this drug is used extensively in infants and children, it\n      has not been extensively studied in this population.\n\n      Physicians do not have very much information on how long it takes for methadone to be\n      removed from the blood circulation and passed out of the body.  Physicians need more\n      information to guide how much and how often we should give methadone to children/young\n      adults to ensure they get the maximum effect with the minimum amount of drug.  During this\n      research study, the study team will collect information about how this drug is processed in\n      infants and children."
        }, 
        "brief_title": "Pharmacokinetics of Multiple Dose Methadone in Children Treated for Opiate Withdrawal", 
        "condition": "Opiate Withdrawal Syndrome", 
        "condition_browse": {
            "mesh_term": "Substance Withdrawal Syndrome"
        }, 
        "detailed_description": {
            "textblock": "A total of approximately 24 to 36 infants and children will participate in this study. This\n      study will be done at five medical centers in the United States.\n\n      Treatment will be prescribed by the infant or child's doctor and not by the study team.\n\n      Participants will be divided into 3 groups based on age, ages 3 months to 2 years, ages 2 to\n      6 years, and ages 6 to 18 years.  There will be approximately 8 to 12 participants enrolled\n      in each group.  Additionally, at least 6 overweight or obese participants between ages 2-18\n      years will be included in this study.\n\n      Information collected from each subject's routine medical care will include:\n\n        -  Participant gender, date of birth, race and ethnicity\n\n        -  Pertinent medical history\n\n        -  Laboratory results (blood count and chemistries) from routine testing ordered by the\n           infant or child's regular doctor\n\n        -  Medications of interest the child was given within the 72 hours prior to first dose of\n           methadone administered after consent\n\n        -  Time and dose of methadone administered to the child up to 14 days prior to enrollment\n\n      Study specific information collected will include:\n\n        -  Blood sample collection to measure level of methadone\n\n        -  Baseline WAT-1 score (sedation withdrawal assessment of the infant or child  used to\n           assess symptoms the child/infant may experience when opioid drugs are discontinued).\n\n      The duration of the study will be up to 10 days, comprised of a maximum 5 day treatment\n      period a 5 day observation period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  >90 days - < 18 years of age at the time of first dose of study drug\n\n          -  Receiving enteral methadone as standard of care\n\n          -  Signed informed consent/HIPAA documents by the parent/legal guardian and assent (if\n             applicable)\n\n        Exclusion Criteria:\n\n          -  Previous participation in the study\n\n          -  Subject is receiving ECLS (Extracorporeal Life Support)\n\n          -  < 36 weeks gestational age at birth for children <1 year of age at time of enrollment\n\n          -  Any other condition or chronic illness that in the opinion of the Principal\n\n          -  Investigator makes participation unadvised or unsafe"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "91 Days", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Participants will be divided into 3 groups based on age, ages 3 months to 2 years, ages 2\n        to 6 years, and ages 6 to 18 years.  There will be approximately 8 to 12 participants\n        enrolled in each group.  Additionally, at least 6 overweight or obese participants between\n        ages 2-18 years will be included in this study."
            }
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01945736", 
            "org_study_id": "Pro00044082", 
            "secondary_id": "HHSN27500021"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort 1", 
                "Cohort 2", 
                "Cohort 3"
            ], 
            "description": "To determine the PK of enteral methadone in children > or = 90 days  and <18 years treated for opiate withdrawal per routine medical care.", 
            "intervention_name": "Methadone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Methadone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Opiate withdrawal in children", 
        "lastchanged_date": "March 25, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jennifer.leshko@allkids.org", 
                    "last_name": "Jenny Leshko"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33701"
                    }, 
                    "name": "All Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Michelle Smith, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rsfrazier@chm.edu", 
                    "last_name": "Rachel Frazier"
                }, 
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "64108"
                    }, 
                    "name": "Children's Mercy Hospital"
                }, 
                "investigator": {
                    "last_name": "Jennifer Lowry, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "harrisnl@med.umich.edu", 
                    "last_name": "Nicholas Harris"
                }, 
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "C.S. Mott Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Varsha Bhatt-Mehta, Pharm D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Samantha.Wrenn@duke.edu", 
                    "last_name": "Samantha Wrenn, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27701"
                    }, 
                    "name": "Duke University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Kevin Watt, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "infingep@musc.edu", 
                    "last_name": "Patricia Infinger"
                }, 
                "facility": {
                    "address": {
                        "city": "Charleston", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29425"
                    }, 
                    "name": "Medical University of South Carolina"
                }, 
                "investigator": {
                    "last_name": "Andrew Atz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "3", 
        "official_title": "Pharmacokinetics of Multiple Dose Methadone in Children", 
        "overall_contact": {
            "email": "kevin.watt@duke.edu", 
            "last_name": "Kevin Watt, MD", 
            "phone": "919-668-8556"
        }, 
        "overall_contact_backup": {
            "email": "brian.smith@duke.edu", 
            "last_name": "P. Brian Smith, MD, MHS, MPH", 
            "phone": "919-668-8951"
        }, 
        "overall_official": [
            {
                "affiliation": "Duke Medical Center/Duke Clinical Research Institute", 
                "last_name": "P. Brian Smith, MD, MHS, MPH", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Duke Medical Center/Duke Clinical Research Institute", 
                "last_name": "Kevin Watt, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Apparent oral clearance\nApparent oral volume of distribution\nArea under the curve\nAbsorption rate constant", 
            "measure": "PK Parameters after multiple doses of enteral methadone", 
            "safety_issue": "No", 
            "time_frame": "Maximum of 7 PK samples based on dosing schedule collected over a 5 day period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01945736"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Duke University Medical Center", 
            "investigator_full_name": "Kevin Watt", 
            "investigator_title": "Assistant Professor of Pediatrics", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "PK of methadone's primary metabolite EDDP", 
                "safety_issue": "No", 
                "time_frame": "Maximum of 7 PK samples based on dosing schedule collected over a 5 day period"
            }, 
            {
                "measure": "PK of R- and S-enantiomers of methadone", 
                "safety_issue": "No", 
                "time_frame": "Maximum of 7 PK samples based on dosing schedule collectes over a 5 day period"
            }, 
            {
                "measure": "Correlation between plasma and DBS samples", 
                "safety_issue": "No", 
                "time_frame": "Maximum of 7 PK samples based on dosing schedule collected over a 5 day period"
            }, 
            {
                "measure": "Correlation between plasma and scavenge samples", 
                "safety_issue": "No", 
                "time_frame": "Maximum of 7 PK samples based on dosing schedule collected over a 5 day period"
            }, 
            {
                "measure": "Influence of CYP3A4 and CYP3B6 genetic polymorphisms on methadone PK", 
                "safety_issue": "No", 
                "time_frame": "Maximum of 7 PK samples based on dosing schedule collected over a 5 day period"
            }, 
            {
                "measure": "Methadone pharmacodynamics using the WAT-1", 
                "safety_issue": "No", 
                "time_frame": "Maximum of 7 PK samples based on dosing schedule collected over a 5 day period"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Study days 1-5 and observational days 6-10"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Kevin Watt", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}